Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silence Therapeutics Plc ADR
(NQ:
SLN
)
15.84
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Silence Therapeutics Plc ADR
< Previous
1
2
Next >
Analyst Expectations For Silence Therapeutics's Future
August 16, 2024
Via
Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024
August 15, 2024
Silence Therapeutics just reported results for the second quarter of 2024.
Via
InvestorPlace
The 3 Best Gene Editing Stocks to Buy in August 2024
August 07, 2024
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases.
Via
InvestorPlace
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
July 25, 2024
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it.
Via
InvestorPlace
The Analyst Landscape: 6 Takes On Silence Therapeutics
June 20, 2024
Via
Benzinga
What 7 Analyst Ratings Have To Say About Silence Therapeutics
May 17, 2024
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
April 22, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Silence Therapeutics
March 13, 2024
Via
Benzinga
Where Silence Therapeutics Stands With Analysts
August 17, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Silence Therapeutics
June 26, 2023
Via
Benzinga
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024
May 16, 2024
Silence Therapeutics just reported results for the first quarter of 2024.
Via
InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via
InvestorPlace
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.
Via
InvestorPlace
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
March 14, 2024
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday.
Via
Benzinga
What's Going On With Silence Therapeutics Stock Today?
March 13, 2024
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of...
Via
Benzinga
The Latest Analyst Ratings for Silence Therapeutics
May 11, 2023
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
January 31, 2024
U.S. stocks traded mostly lower, with the Nasdaq Composite falling over 200 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For March 12, 2024
March 12, 2024
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 13, 2023
Via
Benzinga
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
November 01, 2023
Earlier today, Silence Therapeutics plc (NASDAQ: SLN) announced topline results from the multiple-dose component of the APOLLO phase 1 study of zerlasiran (formerly SLN360) in 36 adults with baseline...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
May 08, 2023
Via
Benzinga
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 25, 2023
Tuesday's session saw 286 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
April 24, 2023
On Monday, 147 stocks made new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 17, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 29, 2023
On Wednesday, 81 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
April 21, 2023
During Friday's session, 149 stocks hit new 52-week lows.
Via
Benzinga
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.